Beijing Sun-Novo Pharmaceutical Research (688621) Fundamentals 2026 — P/E 33.6x, Revenue Analysis | SniperIQ
Beijing Sun-Novo Pharmaceutical Research (688621) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.4B, trading at ¥57.15 on the SHH. This SniperIQ fundamentals page covers Beijing Sun-Novo Pharmaceutical Research's valuation (P/E 33.6x, P/B 5.2x), profitability (net margin 15.8%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Sun-Novo Pharmaceutical Research's market cap?
Beijing Sun-Novo Pharmaceutical Research (688621) has a market capitalization of approximately ¥6.4B, trading at ¥57.15 on the SHH. Market cap moves with the live share price.
What is Beijing Sun-Novo Pharmaceutical Research's P/E ratio?
Beijing Sun-Novo Pharmaceutical Research's trailing twelve-month P/E ratio is 33.6x, with a price-to-book (P/B) of 5.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Sun-Novo Pharmaceutical Research?
Beijing Sun-Novo Pharmaceutical Research runs a net profit margin of 15.8%, a gross margin of 55.0%, and an operating margin of 16.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Sun-Novo Pharmaceutical Research generate?
Beijing Sun-Novo Pharmaceutical Research reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥204M and earnings per share (EPS) of 1.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Sun-Novo Pharmaceutical Research pay a dividend?
Beijing Sun-Novo Pharmaceutical Research offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Sun-Novo Pharmaceutical Research financially healthy?
Beijing Sun-Novo Pharmaceutical Research carries a debt-to-equity ratio of 0.46x and a current ratio of 1.79x, with a market beta of -0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Sun-Novo Pharmaceutical Research a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Sun-Novo Pharmaceutical Research (688621) the key facts are: market cap ¥6.4B, P/E 33.6x, revenue ¥1.2B, 52-week range 46.68-86.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Sun-Novo Pharmaceutical Research's full fundamentals live
Get Beijing Sun-Novo Pharmaceutical Research's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.